Michael Risbano, MD
Critical Care Medicine · Pittsburgh, PANPI 1457307589
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,995 of the $34,230 with a category attached, or 73.0%. 21 manufacturers reported payments, led by Merck at 52.0% of the total. 2025 is the largest year on record at $16,568, more than ten times the $547 reported in 2019. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $241.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$18K
- Actelion Pharmaceuticals US, Inc.$6K
- Chiesi USA, Inc.$5K
- United Therapeutics Corporation$2K
- Gilead$2K
- Bayer$478
- plus $1K from 15 others
Across 58 payments — averaging $3125.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$110K
- Janssen Research & Development, LLC$56K
- Actelion Pharmaceuticals US, Inc.$9K
- Actelion Pharmaceuticals, Ltd$5K
- Acceleron Pharma, Inc.$700
What the payments were for
- Consulting fees$24,99573%
- Travel & lodging$4,71114%
- Food & beverage$4,49013%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 31 | $17,804 |
| Actelion Pharmaceuticals US, Inc. | 8 | $6,211 |
| Chiesi USA, Inc. | 6 | $4,737 |
| United Therapeutics Corporation | 33 | $1,800 |
| Gilead | 1 | $1,730 |
| Bayer | 6 | $478 |
| Amgen | 17 | $341 |
| Liquidia Technologies, Inc. | 2 | $226 |
| Boehringer Ingelheim | 10 | $190 |
| Boston Scientific | 1 | $156 |
| Amarin Pharma, Inc. | 6 | $124 |
| Sandoz | 4 | $76 |
| Lexicon Pharmaceuticals, Inc. | 2 | $68 |
| Janssen Research & Development, LLC | 1 | $60 |
| AstraZeneca | 4 | $57 |
| Johnson & Johnson | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,230 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 48 | $1,116,928 |
| Tyvaso DpiTreprostinil | 45 | $1,064,250 |
| WinrevairSotatercept-Csrk | 43 | $618,913 |
| AdempasRiociguat | 25 | $350,366 |
| OpsumitMacitentan | 20 | $256,943 |
| Ambrisentan | 53 | $195,771 |
| Tadalafil | 78 | $178,236 |
| JardianceEmpagliflozin | 65 | $39,643 |
| Sildenafil Citrate | 37 | $27,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,580 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,532 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,450 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,246 |
| Potassium Chloride | 43 | $649 |
| Furosemide | 49 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $6,211 | $1,373,87168 claims |
| MerckWinrevair | $17,804 | $618,91343 claims |
| BayerAdempas | $478 | $350,36625 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $190 | $45,09476 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Pittsburgh
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Kees PoldermanPittsburgh$85K
- Raghavan MuruganPittsburgh$33K
- Eric BihlerPittsburgh$22K
- Tiffany DumontPittsburgh$21K
- Amy SchmetzerPittsburgh$13K
- Stephanie BaltajiPittsburgh$10K
- Billie BarkerPittsburgh$10K
- Douglas WhitePittsburgh$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.